In the meantime, the ongoing, open-label, randomized FIGHT-302 phase III trial is currently comparing pemigatinib versus CisGem as first-line treatments in unresectable or metastatic CCA harboring FGFR2 rearrangement. Here, FGFR2 is linked to cholangiocarcinoma.